Medicare Enrolled
Dr. Christopher Maisel, MD
Hematology & Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Maisel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Maisel?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Maisel
Dr. Christopher Maisel is a hematology & oncology specialist in Dallas, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Maisel performed 25,745 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Maisel received a total of $774,627 from 47 pharmaceutical and/or device companies across 827 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Maisel is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 31% volume in TX
$774,627 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗25,745
Medicare services
Top 31% in TX for hematology & oncology
Not available
Unique patients (not deduplicated)
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 7,600 | $43 | $137 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
4,900 | $0 | $3 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,350 | $0 | $5 |
| Paclitaxel chemotherapy injection | 3,438 | $0 | $8 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
869 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
530 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
511 | $8 | $36 |
| Anti-nausea injection (Aloxi/palonosetron) | 480 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 420 | $0 | $24 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
414 | $91 | $368 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
309 | $10 | $64 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
158 | $23 | $157 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 154 | $3 | $373 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
138 | $103 | $707 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
134 | $16 | $60 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
121 | $2 | $300 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
119 | $13 | $60 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
117 | $12 | $108 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
89 | $64 | $250 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
76 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
76 | $6 | $34 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
61 | $7 | $431 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
58 | $137 | $496 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
52 | $58 | $211 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
52 | $52 | $344 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
47 | $49 | $313 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
46 | $1 | $7 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
43 | $59 | $821 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
43 | $11 | $96 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
35 | $187 | $1,067 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
35 | $92 | $357 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
34 | $6 | $31 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
34 | $35 | $143 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
34 | $1 | $8 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
27 | $23 | $161 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
24 | $62 | $247 |
| Basic metabolic blood panel A blood test that measures a group of basic chemicals, including total calcium levels. |
21 | $8 | $49 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
20 | $2 | $19 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
18 | $16 | $100 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
16 | $125 | $565 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
15 | $16 | $94 |
| New patient office visit, complex (60-74 min) | 15 | $174 | $709 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
12 | $50 | $686 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.7% high complexity
88.4% medium
9.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$774,627
Total received (2018-2024)
Avg $110,661/year across 7 years
Top 1% in TX for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
827
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$86,640
2023
$130,347
2022
$146,093
2021
$69,690
2020
$106,155
2019
$108,326
2018
$127,375
Payments by company (2024)
Blueprint Medicines Corporation
$30,848
Kite Pharma, Inc.
$17,223
Janssen Biotech, Inc.
$15,958
ADC Therapeutics America, Inc.
$11,637
E.R. Squibb & Sons, L.L.C.
$5,390
AstraZeneca Pharmaceuticals LP
$3,631
Celgene Corporation
$1,200
PFIZER INC.
$128
GENZYME CORPORATION
$119
Rigel Pharmaceuticals, Inc.
$65
Merck Sharp & Dohme LLC
$57
SOBI, INC
$51
Lilly USA, LLC
$46
SERVIER PHARMACEUTICALS LLC
$43
Emmaus Medical, Inc.
$33
Astellas Pharma US Inc
$31
JAZZ PHARMACEUTICALS INC.
$29
ABBVIE INC.
$27
Adaptive Biotechnologies Corporation
$26
GlaxoSmithKline, LLC.
$23
BeiGene USA, Inc.
$23
Incyte Corporation
$22
Genmab U.S., Inc.
$15
Novartis Pharmaceuticals Corporation
$14
Top 3 companies account for 73.9% of 2024 payments
All-time payments by company (2018-2024) ›
Kite Pharma, Inc.
$120,730
Blueprint Medicines Corporation
$99,527
Janssen Biotech, Inc.
$81,098
Karyopharm Therapeutics Inc.
$76,002
Incyte Corporation
$74,449
ADC Therapeutics America, Inc.
$70,027
Celgene Corporation
$52,972
Amgen Inc.
$42,643
Takeda Pharmaceuticals U.S.A., Inc.
$40,907
E.R. Squibb & Sons, L.L.C.
$39,627
GlaxoSmithKline, LLC.
$23,545
Verastem, Inc.
$15,439
AstraZeneca Pharmaceuticals LP
$15,137
Janssen Scientific Affairs, LLC
$13,469
Gilead Sciences, Inc.
$2,814
Genentech USA, Inc.
$2,727
Bayer HealthCare Pharmaceuticals Inc.
$1,140
GENZYME CORPORATION
$328
Rigel Pharmaceuticals, Inc.
$180
ABBVIE INC.
$160
SOBI, INC
$133
Novartis Pharmaceuticals Corporation
$132
PFIZER INC.
$128
Emmaus Medical, Inc.
$122
Adaptive Biotechnologies Corporation
$113
Seagen Inc.
$107
CTI BioPharma Corp.
$92
JAZZ PHARMACEUTICALS INC.
$87
SERVIER PHARMACEUTICALS LLC
$87
PharmaEssentia USA Corporation
$79
Siemens Medical Solutions USA, Inc.
$79
BeiGene USA, Inc.
$67
Lilly USA, LLC
$64
Merck Sharp & Dohme LLC
$57
Ipsen Biopharmaceuticals, Inc
$53
Dova Pharmaceuticals
$48
MorphoSys, US Inc.
$38
Genmab U.S., Inc.
$32
Epizyme, Inc.,
$32
Astellas Pharma US Inc
$31
AbbVie Inc.
$24
Daiichi Sankyo Inc.
$23
Sobi, Inc
$20
RECORDATI_RARE_DISEASES_INC.
$17
AbbVie, Inc.
$15
Taiho Oncology, Inc.
$14
Tactile Systems Technology Inc
$13
Top 3 companies account for 38.9% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ALTUVIIIO · AYVAKIT · Aliqopa · BESREMI · BLENREP · BOSULIF · BRUKINSA · Blincyto · CALQUENCE · CARVYKTI · Copiktra · DARZALEX · DOPTELET · Doptelet · ELREXFIO · ENJAYMO · EPKINLY · Endari · Epkinly · Flexitouch Plus · Gamifant · ICLUSIG · IMBRUVICA · INREBIC · JAKAFI · JAYPIRCA · KEYTRUDA · Kyprolis · LONSURF · MONJUVI · Molecular Accessories · Molecular Reagents/Test Kit/Clinical Utilization · NINLARO · Neulasta · OJJAARA · ONGLYZA · ONUREG · PROMACTA · Pomalyst · REBLOZYL · Revlimid · Rezlidhia · Rituxan · SARCLISA · SCEMBLIX · SYLVANT · TAGRISSO · TASIGNA · TAZVERIK · TECVAYLI · Tavalisse · Tazverik · Tecartus · Tibsovo · VELCADE · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vonjo · XGEVA · XPOVIO · Xospata · Yescarta · ZEPZELCA · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
129
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Maisel is a mixed practice specialist, with moderate Medicare volume, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Maisel experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Maisel performed 7,600 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Maisel receive payments from pharmaceutical companies?
Yes. Dr. Maisel received a total of $774,627 from 47 companies across 827 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Maisel's costs compare to other hematology & oncology specialists in Dallas?
Dr. Maisel's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Maisel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Dallas
Browse hematology & oncology specialists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Kite Pharma, Inc. Payments to Doctors
See all physicians who received payments from Kite Pharma, Inc.
By company
Blueprint Medicines Corporation Payments to Doctors
See all physicians who received payments from Blueprint Medicines Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology